Clinical trials: Patient With Schizophrenia Spectrum Disorder
- Condition Patient With Schizophrenia Spectrum Disorder
- Funder type Industry (pharma, biotech, devices)
Schizophrenia
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
Study to learn if the alternate formulation is effective in agitated schizophrenic patients
- Trial name
- NCT00036127
- Testing
- aripiprazole
- Where
- 16 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia
The purpose of this study will be to evaluate the safety and treatment response of paliperidone palmitate administered to Chinese patients with schizophrenia.
- Trial name
- NCT01947803
- Testing
- Paliperidone Palmitate
- Where
- 12 sites in China
- Volunteers
- 353 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
The objective of this study is to demonstrate that there is a benefit in switching chronic schizophrenic patients from conventional antipsychotic to olanzapine in terms of efficacy, neurological safety and patient's outcome.
- Trial name
- NCT00191555
- Testing
- olanzapine, haloperidol
- Where
- 62 sites in France
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
The primary objectives of the study is to confirm if the efficacy of IM olanzapine in patients with schizophrenia is greater than IM placebo by comparing changes from baseline to 2 hours post first IM injection of agitation.
- Trial name
- NCT00640510
- Testing
- Rapid Acting Intramuscular Olanzapine, Isotonic sodium chloride solution
- Where
- 11 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.
- Trial name
- NCT00283179
- Testing
- Aripiprazole, Risperidone
- Where
- Taiwan
- Volunteers
- 83 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Schizophrenia
The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia
The purpose of this study is to examine the long-term economic, functional and clinical outcomes in schizophrenia patients who require a change in antipsychotic treatment, and are changed to either paliperidone extended release…
- Trial name
- POST (NCT00488891)
- Testing
- Paliperidone ER, Atypical antipsychotics (AAP)
- Volunteers
- 43 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Schizophrenia
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy (effectiveness of drug) and safety of the antipsychotic paliperidone ER compared to another antipsychotic, quetiapine, and to placebo in patients who are acutely ill with…
- Trial name
- NCT00334126
- Volunteers
- 399 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease, Psychoses
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
- Trial name
- NCT00095810
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Psychotic Disorders
Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis
The purpose of this research study is to see how well patients in an early phase of their illness respond to treatment and whether this depends on how well they functioned socially, academically and vocationally before becoming…
- Conditions
- Schizophrenia, Psychotic Disorders, Schizoaffective Disorder
- Trial name
- NCT00369239
- Testing
- risperidone long acting injectable
- Volunteers
- 303 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Body Weight Change, Schizophrenia
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
- Conditions
- Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00095524
- Testing
- Aripiprazole
- Where
- 32 sites in United States, Brazil and 1 more
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorders, Psychotic Disorders
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized…
- Conditions
- Depressive Disorders, Psychotic Disorders, Depression
- Trial name
- NCT00844922
- Testing
- SCH 900636
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics
The purpose of this study is to assess the effectiveness, safety and tolerability of flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated by oral antipsychotics and with acute…
- Trial name
- NCT01685931
- Testing
- Paliperidone Palmitate
- Where
- 17 sites in China
- Volunteers
- 617 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia
- Trial name
- NCT00712686
- Testing
- Aripiprazole, Olanzapine
- Volunteers
- 690 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Lithium Drug-Drug Interaction Study With Lurasidone HCl
The purpose of this study is to evaluate the drug-drug interaction effect between Lithium and Lurasidone HCl.
- Trial name
- NCT01074073
- Testing
- Lurasidone HCl
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals